Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716730 | 0.91 | CYP11B2 (0.38) | MEN1KMT2AGAAPPARGPPARA | |
| SCHEMBL6710015 | 0.90 | KCNMA1 (0.40) | MEN1KMT2AMAPTUSP2TP53 | |
| SCHEMBL6709920 | 0.88 | MAPK14 (0.40) | RAB9ANPC1CYP11B2CYP11B1MAOB | |
| SCHEMBL6711516 | 0.87 | MAPK14 (0.43) | RECQL | |
| SCHEMBL933685 | 0.86 | DGAT1 (0.43) | MEN1KMT2AMAPTTP53GAA | |
| SCHEMBL29898841 | 0.86 | DGAT1 (0.43) | MEN1KMT2AMAPTTP53GAA | |
| SCHEMBL6710179 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2AGAAALOX15TSHR | |
| SCHEMBL26982329 | 0.83 | PDE2A (0.42) | GAAPPARGPPARAHPGDSMN1; SMN2 | |
| SCHEMBL6711346 | 0.82 | MEN1 (0.44) | MEN1KMT2AMAPTGAATSHR | |
| SCHEMBL6712717 | 0.80 | ALDH1A1 (0.40) | MEN1KMT2AMAPTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-4301745-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | King's College London (GB) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022185055-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2022-09-09 | — | — | WO | disclosed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| EP-0898566-B1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL NV (NL) | 2002-11-06 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | HCN2, HCN1, HCN3 | MEN1 3809/4885KMT2A 3966/4885MAPT 3427/4885 |
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | MEN1 3408/4885KMT2A 1807/4885MAPT 357/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | MEN1 3408/4885KMT2A 1807/4885MAPT 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.